Busan, South Korea – Marking a major step in its COVID-19 vaccination efforts, Busan City has announced the launch of the Novavax XBB.1.5 vaccine, adding to its arsenal of Pfizer and Moderna’s XBB.1.5 formulations. Effective today, the city embarks on a widespread, free vaccination campaign targeting all residents aged 12 and up, slated to run until March of the following year.
Employing recombinant genetic technology akin to that used in hepatitis B and influenza vaccines, the Novavax XBB.1.5 is a synthetic antigen vaccine. It operates by directly introducing antigen proteins into the body, stimulating the immune system to produce virus-fighting antibodies.
Esteemed for its safety, this vaccine represents a trusted choice, particularly for those wary of mRNA vaccines’ potential side effects. The Novavax vaccine, specifically targeting the XBB.1.5 variant, broadens its reach to encompass all citizens over 12, including the elderly and immunocompromised individuals.
Administered in a 0.5-milliliter intramuscular injection, the vaccine necessitates only a single dose, irrespective of past vaccination types or schedules. Individuals are eligible for this vaccine three months following any primary or booster dose.
The vaccine not only effectively combats the current dominant virus strain but also significantly lowers the risk of severe outcomes, such as hospitalization and death, following infection. Compared to earlier versions, the XBB.1.5 vaccines, including those by Pfizer, Moderna, and now Novavax, have demonstrated a reduction in adverse reaction rates, with most side effects being of mild to moderate severity.
Participating in the immunization drive are over 320 local healthcare facilities. Residents can book their vaccination through the Korea Disease Control and Prevention Agency’s official website (ncv.kdca.go.kr) or arrange for a same-day shot by contacting a nearby medical center.
Highlighting the importance of this initiative, a Busan City representative underscored the heightened vulnerability of the elderly to COVID-19, stating, “Seniors over 65 are at a significantly increased risk of severe illness and death from the virus. We earnestly encourage this age group, especially those previously hesitant about mRNA vaccines, to embrace this opportunity and receive the Novavax XBB.1.5 vaccine for their protection.
